Samstein et al (2019) recently published the largest clinical dataset for immune checkpoint inhibitors (ICIs: PD1/PD-L1 and CTLA4 inhibitors) with treatment outcomes in 1,662 advanced or metastatic cancer patients across 11 cancer types. This evidence concerns the gene CD274 and cancer.